For many studies, biofluid samples are more easily available than tissue samples. Our Biofluid Biomarker Discovery service enables deep and reproducible quantification of biofluid proteomes. It allows the identification of the most promising, actionable biomarkers to support clinical decision making.
Biofluids are known to have a high dynamic range compared to tissue, requiring a highly robust technology for proteomic analysis. The Biofluid Biomarker Discovery service is based on Biognosys’ proprietary Hyper Reaction Monitoring (HRM™) technology, enabling the quantification of biofluid proteomes with great specificity and depth.
Depending on the sample type, the application offers a depth of up to 5,000 proteins to identify differentially regulated proteins as biomarker candidates in an unbiased, hypothesis-free manner. We also provide highly multiplexed targeted proteomics with absolute quantification for customized panels of proteins.
In blood, we offer a choice of standard, non-depleted plasma/serum profiling or depleted plasma/serum profiling.
Our biofluid-based profiling workflows can be combined with our proprietary PQ500 plasma panel. PQ500 is a reference panel for absolute quantification, developed based on our expertise in targeted proteomics.
Biofluid Biomarker Discovery is scalable to thousands of samples at industry-leading throughput.
The results are presented and discussed with you in a dedicated conference call and delivered electronically in PDF and Excel formats.
a) Normalized relative protein intensities for all detected proteins or absolute quantities if stable isotope standards were used
b) Protein annotation (based on Uniprot Knowledgebase)
a) Differentially regulated proteins with regulation factor and p-value
b) Coefficient of variation analysis
c) Multivariate analysis (e.g. PCA)
d) Hierarchical clustering analysis
e) Functional analysis (e.g. GO/Pathway analysis)
f) Custom analysis upon request
Biofluid Biomarker Discovery can be applied on blood plasma or serum, urine, cerebrospinal fluid (CSF), or any other similar biofluid from any species.
Biognosys is committed to providing the best possible results to our customers at the fastest possible project turnaround time.
Introducing our next-generation plasma biomarker discovery solution. True, unbiased discovery in large-scale clinical research is now possible from plasma. Explore every angle of t [...]
Plasma proteomics is increasingly recognized as a fundamental approach to accelerate biomarker discovery and drug development, taking precision medicine to the next level.
The brochure provides you with an overview of the key features and benefits of our next-generation TrueDiscovery™ platform. In addition, it elaborates on our deep and reproducibl [...]
Immunotherapy significantly improved treatment options for patients with NSCLC. However, not all patients respond equally if at all. In a joint study with Curie Institute (Paris, F [...]
Cerebrospinal fluid (CSF) is established as a key matrix that enables interrogation of biological processes within the central nervous system. CSF biomarkers may support the develo [...]
The case study elaborates on the results of our pan-cancer proteomics study. We analyzed 180 plasma samples from lung, breast, colorectal, pancreatic, and prostate cancer using our [...]
Tognetti M et al. The plasma proteome has the potential to enable a holistic analysis of the health state of an individual. However, plasma biomarker discovery is difficul [...]